Home » Stocks » TGTX

TG Therapeutics, Inc. (TGTX)

Stock Price: $40.20 USD 0.35 (0.88%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $40.01 -0.19 (-0.47%) May 7, 6:12 PM
Market Cap 5.69B
Revenue (ttm) 152,000
Net Income (ttm) -279.38M
Shares Out 115.33M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $40.20
Previous Close $39.85
Change ($) 0.35
Change (%) 0.88%
Day's Open 40.33
Day's Range 39.82 - 40.94
Day's Volume 1,030,372
52-Week Range 16.56 - 56.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other stocks mentioned: MRVI, NSTG, SDC, SWAV
1 day ago - Zacks Investment Research

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET

1 week ago - GlobeNewsWire

ULTRA-V Phase 2 trial has reached completion of patient enrollment ULTRA-V Phase 2 trial has reached completion of patient enrollment

2 weeks ago - GlobeNewsWire

Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions

3 weeks ago - GlobeNewsWire

Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET

3 weeks ago - GlobeNewsWire

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and ...

1 month ago - GlobeNewsWire

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Compan...

1 month ago - GlobeNewsWire

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company's novel, glycoen...

2 months ago - GlobeNewsWire

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -24.56% and -5.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET

2 months ago - GlobeNewsWire

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of final results from the Phase 3 GENUINE trial evaluating ublituximab, the Company's inv...

2 months ago - GlobeNewsWire

Large biotechs are taking over small-cap companies (and their cancer treatments) left and right. Could this business be the next target?

Other stocks mentioned: IBB
2 months ago - The Motley Fool

UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

3 months ago - GlobeNewsWire

Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET

3 months ago - GlobeNewsWire

TG Therapeutics CEO on developing treatments for patients with multiple sclerosis

YouTube video

TG Therapeutics CEO Mike Weiss explained the biopharmaceutical company's plans to address the multiple sclerosis drug market and carve a lane away from competitors in the space.

3 months ago - CNBC Television

Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET

4 months ago - GlobeNewsWire

After a protracted wait, TG Therapeutics Inc. (NASDAQ:TGTX) shareholders finally got rewarded for their patience last month when the stock began a rapid climb to its current price of $52. That's a gain ...

4 months ago - GuruFocus

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Other stocks mentioned: BLFS, STAA
4 months ago - Zacks Investment Research

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

These biotech stocks could sink or soar following some important approval decisions slated for the new year.

Other stocks mentioned: BIIB, BLUE
4 months ago - The Motley Fool

Umbralisib and ublituximab have excellent chances of gaining FDA approval for various blood cancers next year. TGTX also recently reported robust data for ublituximab as a treatment for relapsing multip...

4 months ago - Seeking Alpha

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today annou...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeuti...

4 months ago - GlobeNewsWire

TG Therapeutics stock jumped after the biotech firm announced positive top-line results from two phase 3 studies for its Ublituximab treatment of multiple sclerosis patients. The post TG Therapeutics St...

4 months ago - Investors Business Daily

Both studies met their primary endpoint of significantly reducing annualized relapse rate ( ARR ) (p

4 months ago - GlobeNewsWire

Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the third quarter of 2020, which ended on Sept. 30.

Other stocks mentioned: GLW, LOGI, LRCX
4 months ago - GuruFocus

UNITY-CLL: U2 significantly improved progression-free survival over obin utuz u mab plus chlorambucil (HR= 0 .54, p

5 months ago - GlobeNewsWire

U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow

5 months ago - GlobeNewsWire

Since last year, TGTX has executed its programs brilliantly. Cash position also is decent, although I expect some justified dilution before revenue generation.

5 months ago - Seeking Alpha

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigational once da...

5 months ago - GlobeNewsWire

Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET

5 months ago - GlobeNewsWire

Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT

5 months ago - GlobeNewsWire

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and analyze their ...

5 months ago - Insider Monkey

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.

5 months ago - GlobeNewsWire

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR= 0 .54, p

6 months ago - GlobeNewsWire

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the combination o...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Company’s Execut...

7 months ago - GlobeNewsWire

TG Therapeutics (NASDAQ: TGTX) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients with the pr...

8 months ago - Benzinga

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA)...

8 months ago - GlobeNewsWire

TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments.

8 months ago - GlobeNewsWire

Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

9 months ago - Zacks Investment Research

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the C...

10 months ago - GlobeNewsWire

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the compl...

10 months ago - GlobeNewsWire

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymph... [Read more...]

Industry
Biotechnology
IPO Date
Dec 14, 1995
CEO
Michael Weiss
Employees
272
Stock Exchange
NASDAQ
Ticker Symbol
TGTX
Full Company Profile

Financial Performance

In 2020, TGTX's revenue was $152,000, a change of 0.00% compared to the previous year's $152,000. Losses were -$279.38 million, 61.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is 73.14, which is an increase of 81.94% from the latest price.

Price Target
$73.14
(81.94% upside)
Analyst Consensus: Strong Buy